PROCEPT BioRobotics (NASDAQ:PRCT) Downgraded to “Underperform” Rating by Bank of America

Bank of America lowered shares of PROCEPT BioRobotics (NASDAQ:PRCT) from a neutral rating to an underperform rating in a report published on Thursday morning, MarketBeat Ratings reports. The brokerage currently has $20.00 target price on the stock, down from their previous target price of $38.00.

A number of other analysts have also recently weighed in on PRCT. Leerink Partners reissued an “outperform” rating and issued a $55.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday, November 5th. Jefferies Financial Group upgraded PROCEPT BioRobotics from a “hold” rating to a “strong-buy” rating in a research note on Friday, December 12th. TD Cowen dropped their target price on PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Morgan Stanley decreased their price target on PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 2nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ:PRCT opened at $23.63 on Thursday. The firm has a market capitalization of $1.32 billion, a PE ratio of -13.82 and a beta of 0.99. The company has a current ratio of 8.44, a quick ratio of 7.20 and a debt-to-equity ratio of 0.14. PROCEPT BioRobotics has a 1-year low of $19.35 and a 1-year high of $68.70. The business’s 50 day moving average is $30.18 and its 200-day moving average is $33.64.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.21). The firm had revenue of $76.38 million during the quarter, compared to the consensus estimate of $93.70 million. PROCEPT BioRobotics had a negative return on equity of 24.82% and a negative net margin of 31.02%.The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period last year, the business earned ($0.35) earnings per share. Sell-side analysts predict that PROCEPT BioRobotics will post -1.75 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PRCT. Virtu Financial LLC bought a new position in PROCEPT BioRobotics in the 4th quarter valued at $469,000. T. Rowe Price Investment Management Inc. lifted its stake in shares of PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock valued at $102,919,000 after acquiring an additional 1,218,815 shares during the period. Invesco Ltd. boosted its holdings in PROCEPT BioRobotics by 19.8% in the fourth quarter. Invesco Ltd. now owns 43,570 shares of the company’s stock valued at $1,371,000 after acquiring an additional 7,191 shares during the last quarter. EP Wealth Advisors LLC acquired a new stake in PROCEPT BioRobotics in the fourth quarter worth about $300,000. Finally, Mackenzie Financial Corp raised its holdings in PROCEPT BioRobotics by 8.2% during the 4th quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock worth $49,512,000 after purchasing an additional 118,971 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Solid cash runway and improving operating losses — Q4 showed an improved operating loss and the company ended the quarter with roughly $286.5M in cash and total liabilities of $142.2M, which supports near‑term execution. Quiver Quant Earnings Summary
• Positive Sentiment: FY‑2026 revenue guidance range ($390M–$410M) was raised/updated and sits near analyst consensus, giving some multi‑quarter visibility for modeling. Q4 Results & Guidance (GlobeNewswire)
• Neutral Sentiment: Company hosted an Investor Day outlining its multi‑year plan — strategic detail may help longer‑term sentiment but did not offset near‑term headline risk. Investor Day Release
• Negative Sentiment: Earnings and revenue misses — Q4 revenue of ~$76.4M (+11.9% YoY) and diluted loss of $0.53 missed consensus (revenue and EPS), and Q1 revenue guidance ($79M–$82M) came in well below street expectations — the primary catalyst for selling. Q4 Results & Guidance (GlobeNewswire)
• Negative Sentiment: New securities‑fraud investigation announced by law firm Ademi LLP, alleging possible inaccurate statements about financials/operations — this raises regulatory/legal overhang and investor risk. Ademi LLP Investigation
• Negative Sentiment: Multiple analyst price‑target cuts and a Bank of America downgrade to underperform (PT $20) plus cuts from Leerink, TD Cowen and Piper Sandler increased selling pressure; some firms remain constructive but consensus risk has risen. Analyst Coverage/Benzinga TD Cowen Comment
• Negative Sentiment: Heavy institutional selling and a spike in volume pushed the stock to a 52‑week low; hedge‑fund and mutual‑fund position reductions magnified the decline. Quiver Quant (institutional moves) Benzinga: 52‑Week Low

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.